Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
PR Newswire —
Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation following acute injury NEW YORK, March 16, 2026 /PRNewswire/ -- Egret Therapeutics, Inc. ("Egret"), a clinical-stage biotechnology company...